PBIO Clinical trials Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 Published August 07, 2025 at 01:15 PM PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Find similar articles on Candlesense globenewswire